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Aim To investigate the potential tissue-protective effects 
of antioxidants selenomethionine and D-pantethine ap-
plied together with doxorubicin (Dx) on NK/Ly lymphoma-
bearing mice. The impact of this chemotherapy scheme 
on animal survival, blood cell profile, hepatotoxicity, glu-
tathione level, and activity of glutathione-converting en-
zymes in the liver was compared with the action of Dx ap-
plied alone.
Methods The hematological profile of animals was stud-
ied by the analysis of blood smears under light microscopy. 
Hepatotoxicity of studied drugs was evaluated measuring 
the activity of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) enzymes, De Ritis ratio, and coen-
zyme A fractions by McDougal assay. Glutathione level in 
animal tissues was measured with Ellman reagent, and the 
activity of glutathione reductase, transferase, and peroxi-
dase was measured using standard biochemical assays.
Results D-pantethine (500 mg/kg) and, to a lower extent, 
selenomethionine (600 µg/kg) partially reduced the nega-
tive side effects (leukocytopenia and erythropenia) of Dx (5 
mg/kg) in NK/Ly lymphoma bearing animals on the 14th 
day of their treatment. This increased animal survival time 
from 47-48 to 60+ days and improved the quality of their 
life. This ability of D-pantethine and selenomethionine was 
realized via hepatoprotective and immunomodulating ac-
tivities. D-pantethine also restored the levels of acid-sol-
uble and free CoA in the liver of tumor-bearing animals, 
while selenomethionine caused the recovery of glutathi-
one peroxidase levels in the liver, which was significantly 
diminished under Dx treatment. Both compounds de-
creased glutathione level in the liver, which was consider-
ably induced by Dx.
Conclusions Antioxidants selenomethionine and D-pan-
tethine partially reversed the negative side effects of Dx in 
NK/Ly lymphoma-bearing mice and significantly increased 
the therapeutic efficiency of this drug in tumor treatment.
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The vast majority of all agents used to directly kill cancer 
cells (ionizing radiation, most chemotherapeutic agents, 
and some targeted therapies) work through either directly 
or indirectly generating reactive oxygen species that block 
the key steps in the cell cycle (1). That is why in the last two 
decades the use of dietary supplements with antioxidant 
activity in cancer therapy has become extremely popu-
lar with an aim to decrease potential side effects of can-
cer chemotherapy on the organism of cancer patients. It is 
believed that the application of antioxidants can decrease 
side effects of drugs on healthy tissues of patients, but 
have a little influence on the therapeutic toxicity of these 
drugs toward tumors.
Despite nearly two decades of investigations of use of di-
etary antioxidant supplementation during conventional 
chemotherapy and radiation therapy, controversy remains 
about the efficacy and safety of this complementary treat-
ment. Different sources estimate the actual usage of anti-
oxidant supplements by cancer patients in the range be-
tween 13% and 87% (2-4). However, the use of antioxidant 
supplements by patients undergoing chemotherapy has 
been criticized due to the concerns that antioxidants may 
interfere with the mechanism of action of chemotherapy 
and subsequently decrease its efficacy, protecting both 
healthy and tumor cells from oxidative damage (5,6). How-
ever, other data suggest that antioxidants can protect nor-
mal tissues from chemotherapy- or radiation-induced dam-
age without decreasing tumor control, as well as alleviate 
toxic side effects of drugs, allowing patients to tolerate che-
motherapy for the full course of treatment and possibly at 
higher doses (7). As a result, patients may have better tumor 
response rates and increased chances of survival.
The most popular antioxidant supplements used in clinics 
include vitamins A,C,E, melatonin, selenium derivatives, N-
acetylcysteine, and glutathione (8). Inside the cells these 
compounds act either as reducers or lipid chains break-
ers (melatonin, NAC, Vitamin E, GSH, beta carotene, and 
vitamin C) or essential elements of antioxidant enzymes 
formed by combining with a protein to form selenopro-
teins (selenium, GSH) (8). In some cases antioxidants may 
act as metal chelators (Vitamin C, ellagic acid, and dexra-
zoxane) or cellular protectors from free radical attack (vita-
mins A, C, E. and melatonin) (8).
Anthracycline doxorubicin (Dx) is one of the most widely 
used chemotherapeutic agents with a broad spectrum of 
activity. Dx is commonly applied for the treatment of a large 
number of tumor types, including non-Hodgkin’s and Hodg-
kin’s lymphoma, multiple myeloma, as well as lung, ovarian, 
gastric, thyroid, breast, sarcoma, and pediatric cancers (9). 
However, Dx use in cancer treatment is limited by serious 
shortcomings, including cumulative dose-dependent car-
diotoxicity, myelosuppression, and hepatotoxicity (10,11). 
It is considered that these negative side effects are caused 
by excessive production of reactive oxygen species (ROS) in 
the mitochondria of targeted cells. Thus, lowering ROS pro-
duction under Dx treatment by specific antioxidants should 
decrease these side effects, allowing an increase in the maxi-
mum therapeutic dose of the drug, improvement of quality 
of life of cancer patients, and their survival rates.
One of the ways to solve this problem is the use of antioxi-
dant dietary supplements, which can counteract free radi-
cals and prevent their action causing tissue and organ dam-
age (12). The main mechanisms of antioxidants action are 
the suppression of free radicals formation, inhibition of chain 
initiation and/or propagation, reparation and reconstitution 
of cell membranes, or key antioxidant enzymes’ functioning 
as coenzymes, thus greatly enhancing their activity (13).
We have previously reported (14) on a significant modula-
tory effect of selenium derivatives (sodium selenite and sele-
nomethionine) and vitamin B
5 precursor – D-pantethine – 
on cytotoxic activity of anticancer drug doxorubicin (Dx) in 
vitro toward various tumor cell lines. It was also demonstrat-
ed that selenomethionine (SeMet) and D-pantethine (D-Pt) 
partially decreased the side effects of Dx in vivo in healthy 
Wistar rats, however there are no data about their tissue-
protective activity in animal tumor models. It is known that 
selenium plays an important role in the regulation of gluta-
thione system, being a coenzyme of glutathione peroxidase 
(15), while D-Pt is a precursor of coenzyme A, involved in the 
majority of metabolic processes in the cell (16,17).
The main goal of current study was to investigate the ther-
apeutic effect of joint application of SeMet and/or D-Pt 
with Dx in vivo in NK/Ly lymphoma. The impact of this che-
motherapy scheme on animal survival, blood profile, he-
patotoxicity, glutathione level, and activity of glutathione-
converting enzymes in animal tissues was studied and 
compared with the action of Dx alone.
MAteRiALS ANd MethOdS
Studies of the biological activity of selenomethionine (Se-
Met), D-pantethine (D-Pt), and doxorubicin were conducted 
in 2015 at the animal facility of Institute of Cell Biology NAS 
of Ukraine (Lviv, Ukraine). 60 adult male Balb/c mice with 25-
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28 g weight were kept under standard vivarium conditions 
with constant access to the full feed and drinking water. Ani-
mals were divided into 10 groups with 6 mice in each.
Murine NK/Ly lymphoma was obtained from the tumor 
strain collection at R.E. Kavetsky Institute of Experimental Pa-
thology, Oncology and Radiobiology, NAS of Ukraine, Kyiv. 
The ascites tumor was supported by transferring 0.2-0.3 mL 
of ascitic fluid (20-30 mln cells) from donor mouse into the 
abdominal cavity of the recipient mouse. Ascites from the 
tumor-bearing mice was obtained and transplanted on the 
7-8th day after the inoculation. Tumor growth was controlled 
by everyday weighting of mice. The viability and number of 
cells in the ascitic fluid were checked by cell counting in the 
hemocytometric chamber in the presence of 0.05% trypan 
blue. The lymphoma cell vitality in the ascites used for trans-
plantation was not lower than 98%.
Organic selenium derivative Seleno-L-methionine (≥98% 
(TLC)) and D-pantethine (vitamin B5 precursor) were pur-
chased from Sigma (St. Louis, MO, USA), and doxorubicin 
hydrochloride was obtained from Pfizer (New York, NY, 
USA). Antioxidants were dissolved in sterile 0.9% sodium 
chloride solution prior to per os treatment of animals. 1000 
μg dose of L-selenomethionine/kg bw/d (equivalent to 
400 μg selenium/kg bw/d) was reported to be a no-ob-
served-adverse-effect-level (NOAEL) in a 13-week study in 
rats (18). At the same time, no genotoxicity and no carci-
nogenicity has been observed for D-Pt action, and no de-
velopmental toxicity in mice and rats at up to 600 mg/kg 
bw/d doses (19). In our study, animals received cumulative 
dose of 600 µg/kg of SeMet per os and 500 mg/kg of D-Pt 
per os from the 2nd till 20th day after tumor inoculation, 
which is 10-fold lower than NOEAL for both antioxidants, 
to exclude any potential side effects. Mice were divided 
into 10 experimental groups (Figure 1).
Animals were administered selenomethionine (60 µg/kg, 
cumulative dose 600 µg/kg) (groups 3, 6, 9) or D-Pt (50 
mg/kg, cumulative dose 500 mg/kg) (groups 4,7,10) per os 
FiGuRe 1. Mice treatment scheme by anticancer drug and antioxidants.
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every second day, starting from 2nd till 20th day of tumor 
inoculation. The chemotherapy scheme was developed 
based on NCI recommendations (20) and other studies 
describing combined use of anticancer drugs and antioxi-
dants (21,22). Mice from the first (control) and second (NK/
Ly lymphoma, untreated) groups received simultaneously 
the equivalent volume of 0.9% sodium chloride solution 
in a similar mode. Doxorubicin in low (0.5 mg/kg, cumula-
tive dose 5 mg/kg) and higher dose (1 mg/kg, cumulative 
dose 10 mg/kg) was injected intraperitoneally (i.p.) every 
second day starting from 2nd till 20th day of tumor in-
oculation to the animals from 5-7th and 8-10th groups, 
respectively. Treatment of animals with antioxidants in 
groups 6-7, 9-10 took place 1h before Dx injection. Tumor 
growth was monitored by daily weighting of animals, as 
increase in animal weight strongly correlates with NK/Ly 
tumor growth (23)
For studies of glutathione, CoA, and enzyme activities in 
tissues of experimental animals, additional group of ani-
mals was used in another experiment. 30 adult male Balb/c 
mice with 25-28 g weight were divided into 5 groups of 6 
mice each: control (healthy), NK/Ly lymphoma (untreated), 
Dx 5 mg/kg, Dx 5 mg/kg+SeMet 600 µg/kg, and Dx 5 mg/
kg+D-Pt 500 mg/kg. Drugs were administered in the same 
way as mentioned before. Animals were sacrificed at the 
21st day after tumor inoculation by cervical dislocation, 
their organs were removed, washed in saline, and homog-
enized for further studies.
All in vivo experiments were conducted in accordance with 
the international principles of the European Convention for 
protection of vertebrate animals under the control of the 
Bio-Ethics Committee of the above mentioned institution 
(Protocol Nş 9/2015 from 1.09.2015 of the BioEthics com-
mittee of the Institute of Cell Biology, NAS of Ukraine).
For blood sampling, a small part of mouse tail was ampu-
tated, ~ 50 µL of blood was pumped into a test tube, and 
the wound was immediately disinfected with 70% alcohol. 
For red blood cell count 5 µL of blood were dissolved in 
5 mL of isotonic NaCI solution (1:1000 dilution), while for 
leukocyte count 5 µL of blood was dissolved in 95 µL of 
3% acetic acid solution (1:20 dilution). Erythrocytes were 
counted in 5 big squares (divided into 16 small each) of 
hemocytometric Goryaev’s chamber, while leukocytes 
were counted in 100 large squares, grouped by 4, under 
the Evolution 300 Trino microscope (Delta Optical, Mińsk 
Mazowiecki, Poland). The number of erythrocytes and leu-
kocytes was calculated by standard formulas (24).
For blood smear preparation, 3 µL of blood was put at the 
edge of a slide, and then spread for 1.5 cm using another 
narrow polished slide, placed at a 45° angle. The obtained 
smears were dried at room temperature, then fixed with 
absolute methanol, and later rehydrated by subsequent 
washing in ethanol solutions with decreasing concentra-
tions (96%, 75%, 50%, 25%, 12.5%). Finally, the smears were 
washed with distilled water, stained with Giemsa dye us-
ing standard protocol, and air-dried, after which they were 
ready for leukogram analysis.
Light microscopy counting of leukocytes performed under 
Evolution 300 Trino microscope (Delta Optical) on 90 × oil 
immersion objective. Cell counting was always done using 
the same system – half of the cells were counted in the up-
per half part of the smear, and the other 50% of cells were 
counted on the lower part of the smear. The percentage of 
certain types of white blood cells in each smear was de-
termined after counting of at least 300 cells. The obtained 
values (due to differences in absolute numbers of cells in 
each counted smear) were normalized to 100%, and per-
cent values of each leukocyte fraction were calculated as 
described in the work of Wilkinson et al (25).
For determination of aspartate aminotransferase activity, 
10 µl of serum was mixed with 100 µL of substrate solu-
tion (2 mM α-ketoglutaric acid; 0.2 M D,L-aspartate in 0.1 
M phosphate buffer pH 7.4), while in control tube 10 µL 
of distilled water were added instead of serum. The tubes 
were placed for 60 min at 37°C, and then 100 µL of 1mM 
solution of 2,4-dinitrophenylhydrazine was added to the 
samples and left for 20°C at room temperature. After this, 
1 mL of 0.4 M sodium hydroxide solution was added to 
each sample for extra 10 min, and the optical density of the 
samples was measured using Helios Gamma spectropho-
mometer (Thermo Fisher Scientific, Waltham, MA, USA) at 
540 nm wavelength. For alanine aminotransferase activity, 
the procedure was identical, except for substrate solution 
(2 mM α-ketoglutaric acid; 0.2 M DL-alanine in phosphate 
buffer pH 7.4).
For better understanding of the role of studied antioxidants 
on liver functions in NK/Ly lymphoma bearing animals un-
der Dx treatment, glutathione and coenzyme A levels, to-
gether with the activity of glutathione-related enzymes in 
the liver. were studied in more detail.
The measurement of glutathione reductase and glutathi-
one transferase activity was performed according to Carl-
berg et al and Rice-Evans et al, respectively (26,27). Deter-
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mination of glutathione and its redox potential in the liver 
was conducted as previously described (28). The analysis of 
free SH-groups in proteins from blood plasma was done as 
previously described (29).
Glutathione peroxidase activity was measured by two dif-
ferent assays based on use of various peroxide-contain-
ing substrates. In the assay described by Moin et al (30), 
t-BOOH was used as a substrate, while the activity of sele-
nium-specific GPx was measured as described by Krugliko-
va et al (31), with hydrogen peroxide as the main substrate. 
For inhibition of catalase activity, sodium aside was added 
to the incubation mixture.
Identification of coenzyme A fractions was conducted as 
previously described (32,33). Study of the content of free 
form of coenzyme A (CoA-SH) and short chain acyl-CoA 
derivative (acetyl-CoA) in the rat liver was carried out using 
high-performance liquid chromatography HPLC assay on 
a HPLC instrument Agilent 1100/1200 (Agilent Technolo-
gies, Santa Clara, CA, USA). Homogenization of liver tissue 
samples was performed at 4°C using 4% HClO4 at a ratio of 
1:6. The homogenates were centrifuged at 16 000 g for 15 
min at 4°C and the obtained chlorine supernatants were 
adjusted to pH 5 with 20% NaOH. Prior to introduction into 
the chromatograph, the supernatant was filtered through 
a RC filter (0.45 µm, 13 mm) (Agilent Technologies). Zorbax 
SB-C18 chromatographic column, 150 × 3 mm, particle size 
3.5 µm (Agilent Technologies) was used for HPLC.
All experiments were performed in triplicate and repeat-
ed 3 times. Statistical analysis of data due to low number 
of samples per group (n = 6) was conducted in GraphPad 
Prism software (GraphPad Software Inc. La Jolla, CA, USA) 
using non-parametric tests (2-way ANOVA with Bonferroni 
post-hoc tests, which compares replicate values by rows). 
The level of significance was set to be lower than 0.05.
ReSuLtS
Selenomethionine and d-pantethine increase survival 
time of NK/Ly lymphoma bearing animals treated with 
dx
Data on survival of animals treated with various cumula-
tive doses of Dx (5 mg/kg and 10 mg/kg), SeMet (600 µg/
kg), and/or D-Pt (500 mg/kg) are presented in Figure 2. Ap-
plication of SeMet (cumulative dose 600 µg/kg) and D-Pt 
(cumulative dose 500 mg/kg) had a little impact on ani-
mal survival (up to 23-25 days). However, both compounds 
revealed moderate anticancer activity, as they decreased 
2-fold the volume of ascitic fluid in comparison with the 
control group (P < 0.01 for SeMet at 19th day of tumor in-
oculation, but non-significant for D-Pt) (Figure 3A). Treat-
ment of animals with Dx (5 mg/kg) significantly increased 
animal survival in comparison with the control – up to 48 
days after tumor inoculation, but none of them survived till 
the end of experiment (60 days). Joint application of SeMet 
(600 µg/kg) and Dx (5 mg/kg) led to a complete remission 
in 33% of animals (survival >60 days) (Figure 2A). Combina-
tion therapy with D-Pt (500 mg/kg) and Dx (5 mg/kg) was 
even more effective, leading to tumor remission in 100% 
animals (Figure 2A), thus suggesting a prominent thera-
peutic efficiency of D-Pt in combination with low doses 
of Dx. These data were also supported by animal weight 
studies, which have shown an enhancement of antican-
cer activity of Dx by SeMet (P < 0.01 at 13th day) and D-Pt 
(P < 0.05 at 13th day) in the period from the 10th to 18th 
day after tumor inoculation (Figure 3B).
Higher doses of Dx (10 mg/kg), in contrast to lower dos-
es (5 mg/kg), cured 100% animals with NK/Ly lympho-
ma (survival >60 days) (Figure 2B). However, in this case 
therapeutic effect of SeMet and D-Pt was much lower 
(P < 0.001) compared to their action in combination with 
FiGuRe 2. Survival of animals with NK/Ly lymphoma treated with various concentrations of dx and antioxidant compounds.
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5 mg/kg dose of Dx, and only 33% animals treated with 
these antioxidants and Dx survived for more than 60 days, 
while other 67% died at the 36th-52nd day after tumor in-
oculation (Figure 2B). However, animal survival data con-
tradict to animal weight studies (Figure 3C), which clear-
ly show beneficial effects of dietary supplements, which 
neutralized the weight loss (5%-10%) observed in all Dx-
treated animals.
SeMet and d-pantethine decrease myelosuppressive 
effects of dx in tumor-bearing animals
For in-depth studies of the impact of antioxidants on my-
elosupressive activity of Dx blood smears were prepared 
from NK/Ly lymphoma-bearing animals at the 14th and 
21nd day after tumor inoculation, and were compared 
with such smears, prepared from blood of healthy (con-
trol) animals (Table 1, Figure 4, Figure 5).
Despite the therapeutic effect of Dx on NK/Ly lymphoma, 
this drug in 5 mg/kg dose also caused severe side effects 
on hematopoietic system, namely inducing erythropenia. 
Both SeMet and D-Pt restored the number of erythrocytes 
almost to the number of control samples (Table 1, Figure 
4). The same tendency was observed for changes in leu-
kocytes number, which also significantly decreased under 
Dx treatment (P < 0.001 at 14th day), while both SeMet and 
D-Pt restored these indices almost to the control level on 
the 14th and 21st day (Table 1, Figure 4).
The development of NK/Ly lymphoma significantly 
(P < 0.001) increased the level of segmented neutrophils, 
while Dx (5 mg/kg) decreased this index both at the 14th 
and 21st day after tumor inoculation, suggesting a ther-
apeutic effect of this drug (Table 1, Figure 5). However, 
combined therapy with SeMet (600 µg/kg) and Dx (5 mg/
kg) led to 20% more decrease in the level of segmented 
neutrophils, while D-Pt (500 mg/kg) decreased this index 
even stronger (1.8-fold lower compared to the action of 
Dx alone).
The number of small lymphocytes (T- and B-lymphocytes) 
is another important index that is rapidly decreased in tu-
mor-bearing animals compared to control (Table 1, Figure 
5). Dx (5 mg/kg) partially restored this index at the 14th 
and 21st day after tumor inoculation, while SeMet and 
D-Pt applied together with this drug, increased it 1.5- and 
2.2-fold on the 14th day, respectively (Table 1). On the 21st 
day, such an effect of antioxidants was also preserved (re-
versal of the number of small lymphocytes almost to the 
control level), but due to further increase of this index in Dx 
group, the differences between them were less expressed 
(Table 1, Figure 5).
The same tendencies were observed when animals were 
treated with antioxidants and higher dose of Dx (10 mg/
kg) (Table 1, Figure 4, Figure 5). Dx (10 mg/kg) caused even 
more severe side effects when it comes to the number of 
erythrocytes compared to control, while SeMet effectively 
restored this index to the control level, and D-Pt demon-
strated even higher efficiency (Table 1). Another specific 
feature of Dx is development of monocytosis in treated an-
imals, as observed using both drug doses on the 21st day 
after tumor inoculation, and D-Pt was the only compound 
FiGuRe 3. Changes in the weight of animals with NK/Ly 
lymphoma treated with various concentrations of dx and 
antioxidant compounds.
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that effectively normalized this index to the control level 
(Table 1, Figure 5).
We did not found any major differences in the impact of 
Dx and Dx + antioxidants on the ratio of segmented neu-
FiGuRe 4. Comparison of the number of erythrocytes and leukocytes in NK/Ly lymphoma-bearing animals treated with various 
concentrations of dx and antioxidant compounds, on the 14th and 21st day after tumor inoculation. *P < 0.05 related to 14th day, 
**P < 0.01 related to 14th day, ***P < 0.001 related to the 14th day.
tAbLe 1. impact of doxorubicin, selenomethionine, and d-pantethine on blood formula of NK/Ly lymphoma bearing mice on the 
14th day and 21st day after tumor inoculation (M±Sd)
14th day
Groups WbC, (*103/mL) RbC, (*109/mL) SN (%) RSN (%) SL (%) bL (%) M (%)
Control (healthy)  6.6 ± 0.3 8.8 ± 0.9 24.3 ± 1.4 2.0 ± 0.5 57.0 ± 3.2 14.0 ± 1.9  2.7 ± 0.3
Group I (C, NK/Ly) 11.4 ± 2.6*** 7.9 ± 1.3 63.3 ± 2.9*** 5.0 ± 0.4 20.2 ± 1.8***  6.7 ± 0.4**  4.8 ± 0.2**
Group II (Se-Met)  9.4 ± 0.1** 5.9 ± 0.6*** 61.0 ± 1.0*** 2.7 ± 0.2 24.5 ± 1.5***  9.5 ± 0.5  2.3 ± 0.2
Group III (D-Pt)  8.9 ± 0.1** 5.8 ± 0.1*** 53.8 ± 1.8 7.1 ± 1.0 24.8 ± 2.3***  8.5 ± 0.0  5.9 ± 0.6
Group IV (Dx 5)  5.4 ± 0.1** 6.8 ± 0.3 53.7 ± 0.6 3.3 ± 0.1 24.0 ± 1.0*** 14.1 ± 1.4  5.0 ± 0.4
Group V (Dx 5+Se-Met)  6.6 ± 0.3 8.6 ± 1.7 40.0 ± 0.8 2.8 ± 0.2 39.0 ± 0.8 15.0 ± 0.8  3.2 ± 0.6
Group VI (Dx 5+D-Pt)  7.3 ± 0.3 9.1 ± 1.7 29.8 ± 0.4 3.1 ± 0.8 53.4 ± 1.4 10.6 ± 0.4  3.1 ± 0.2
Group VII (Dx 10)  4.1 ± 0.2*** 5.8 ± 0.1*** 45.8 ± 2.3 2.7 ± 0.2 32.0 ± 2.0 14.0 ± 0.0  5.7 ± 0.2
Group VIII (Dx 10+Se-Met)  6.1 ± 1.2## 8.6 ± 0.7### 41.7 ± 1.2 3.0 ± 0.1 40.0 ± 0.8### 13.0 ± 0.8  2.4 ± 0.8###
Group IX (Dx 10+D-Pt)  7.1 ± 1.2### 8.9 ± 1.1### 27.7 ± 3.8### 2.5 ± 0.4 41.1 ± 0.7### 15.9 ± 0.7 11.5 ± 0.6###
21st day
Groups WbC, (*103/ml) RbC, (*109/ml) SN (%) RSN (%) SL (%) bL (%) M(%)
Control (healthy)  6.6 ± 0.3  8.8 ± 0.9 24.3 ± 1.4 2.0 ± 0.5 57.0 ± 3.2 14.0 ± 1.9  2.7 ± 0.3
Group I (C, NK/Ly) 23.1 ± 2.8*** 12.2 ± 0.2 71.2 ± 0.1*** 4.1 ± 0.4 16.9 ± 1.1***  5.0 ± 0.2***  4.8 ± 1.0**
Group II (Se-Met) 11.6 ± 1.2***  6.8 ± 1.6 71.0 ± 2.5 2.2 ± 0.2 18.0 ± 7.3***  4.6 ± 0.6  4.3 ± 1.3
Group III (D-Pt) 12.5 ± 0.6***  6.5 ± 1.3 74.5 ± 0.4 1.3 ± 0.5 12.8 ± 2.7***  5.8 ± 1.3  5.6 ± 2.1
Group IV (Dx 5)  5.7 ± 0.8  8.2 ± 1.1 38.2 ± 2.2 2.3 ± 0.5 35.4 ± 0.4 13.3 ± 0.3 10.6 ± 2.5
Group V (Dx 5+Se-Met)  6.8 ± 1.0  8.7 ± 1.1 40.5 ± 3.0 1.8 ± 0.3 43.1 ± 3.0  7.6 ± 1.4  6.6 ± 3.0
Group VI (Dx 5+D-Pt)  5.7 ± 0.8 11.7 ± 0.9 36.5 ± 1.1 1.7 ± 0.1 51.0 ± 2.0  6.1 ± 1.2  4.7 ± 1.1
Group VII (Dx 10)  5.0 ± 1.1  7.1 ± 0.5 21.7 ± 2.4 3.0 ± 0.0 56.6 ± 1.5 12.9 ± 0.2 10.1 ± 1.8
Group VIII (Dx 10+Se-Met)  6.1 ± 0.5 10.8 ± 0.9### 40.8 ± 2.4### 3.8 ± 0.5 28.1 ± 1.8### 14.7 ± 0.7 12.6 ± 1.1
Group IX (Dx 10+D-Pt)  9.6 ± 0.9### 10.6 ± 0.3### 23.8 ± 4.4 2.5 ± 0.6 50.2 ± 1.9## 10.3 ± 0.8 5.2 ± 0.2###
RbC – red blood cells; WbC – while blood cells; RSN – neutrophils with ring-shaped nuclei.
SN – neutrophils with segmented nuclei; SL – small lymphocytes; bL – big lymphocytes; M – monocytes.
* P < 0.05 related to control, **P < 0.01 related to control, ***P < 0.001 related to control,  P < 0.001 related to control(NK/Ly); P < 0.05 related to 
dx 5 mg/kg, P < 0.001 related to dx 5 mg/kg, ##– P < 0.01 related to dx 10 mg/kg; ###– P < 0.001 related to dx 10 mg/kg.
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trophils and small lymphocytes, due to fact that Dx (10 
mg/kg) itself restored these indices almost to the control 
level, compared to the untreated animals (Table 1). Thus, 
both antioxidants stopped leukopenia, erythrocytopenia, 
and monocytosis induced by Dx, but they had no immu-
nomodulating impact (due to high comparative basis of 
Dx alone) on the ratio of segmented neutrophils and small 
lymphocytes under action of high doses of this drug.
SeMet and d-pantethine partially modulate 
hepatotoxicity of dx
At the last stage of our studies, the therapeutic impact of 
antioxidants on the liver metabolism in Dx-treated animals 
was analyzed. For this, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels were measured, 
which are considered to be the most widely used hepato-
FiGuRe 5. Changes in leukogram in NK/Ly lymphoma-bearing animals treated with various concentrations of dx and antioxidant 
compounds, on the 14th and 21st day after tumor inoculation. **P < 0.01 related to the 14th day, ***P < 0.001 related to the 14th day.
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toxicity tests (34). The growth of NK/Ly lymphoma sharply 
increased AST levels, while action of SeMet and D-Pt alone 
enhanced it even further on the 21st day, which may in-
dicate potential hepatotoxicity of these dietary supple-
ments only in tumor-bearing animals (Table 2 and Figure 
6). Dx possesses moderate hepatotoxicity (35), which de-
veloped only on the 21st day after tumor inoculation (Fig-
ure 6). However, combined treatment with Dx and studied 
compounds revealed the opposite tendency – decrease in 
hepatotoxic effects, caused by Dx, SeMet, and D-Pt (Figure 
6). The strongest effect of the tested dietary supplements 
was observed when they were applied with a high dose 
of Dx (10 mg/kg), thus confirming their strong tissue-pro-
tecting properties. The same tendencies of antioxidants 
action were observed for alanine aminotransferase (ALT), 
though they were not statistically significant (Table 2, Fig-
ure 6). Analysis of ALT/AST coefficient (De Ritis ratio), which 
is considered to be a well-known hepatotoxicity index (36), 
confirmed strong cytoprotective properties for D-Pt, which 
reversed Dx-induced hepatotoxicity to the control level 
(Table 1, Figure 6).
A sharp increase in the level of reduced glutathione was 
observed in the liver of NK/Ly-lymphoma bearing mice al-
ready on the 14th day after tumor inoculation (Table 3). 
This event was also accompanied by a significant increase 
(P < 0.05) in the degree of reduction of its redox potential 
compared to healthy animals. Doxorubicin treatment had 
no significant impact on elevated concentration of re-
duced glutathione in the liver, but joint application of Dx 
FiGuRe 6. Changes in the activity of aspartate aminotransferase and alanine aminotransferase in NK/Ly lymphoma bearing animals 
and antioxidant compounds, on the 14th and 21st day after tumor inoculation. ***P < 0.001 related to the 14th day.
tAbLe 2. impact of doxorubicin, selenomethionine, and d-pantethine on ALt/ASt levels and de Ritis ratio in the serum of NK/Ly 
lymphoma bearing mice on 14th day and 21st day after tumor inoculation (M±Sd)
14th day 21st day
Groups ALt, units/ml ASt, units/ml de Ritis ratio ALt, units/ml ASt, units/ml de Ritis ratio
Control (healthy) 0.9 ± 0.16 1.4 ± 0.36 1.5 ± 0.20 0.9 ± 0.16 1.4 ± 0.36 1.5 ± 0.20
Group I (C, NK/Ly) 1.2 ± 0.25 2.9 ± 0.38 2.4 ± 0.33 2.00 ± 0.53 5.1 ± 0.97 2.5 ± 0.29*
Group II (Se-Met) 1.1 ± 0.22 2.1 ± 0.34 1.9 ± 0.09 2.00 ± 0.62 6.9 ± 0.84 3.4 ± 0.68***
Group III (D-Pt) 1.6 ± 0.17 2.2 ± 0.72 1.4 ± 0.32 3.4 ± 0.86 7.5 ± 0.87 2.2 ± 0.33
Group IV (Dx 5) 1.4 ± 0.53 2.4 ± 0.11 1.7 ± 0.61 1.4 ± 0.32 2.9 ± 0.84 1.9 ± 0.91
Group V (Dx 5+Se-Met) 0.6 ± 0.21 1.1 ± 0.05 1.8 ± 0.79 1.1 ± 0.14 2.7 ± 0.36 2.5 ± 0.70
Group VI (Dx 5+D-Pt) 0.5 ± 0.21 1.2 ± 0.24 2.4 ± 0.16 1.6 ± 0.34 2.8 ± 0.91 1.7 ± 0.14
Group VII (Dx 10) 1.2 ± 0.26 2.0 ± 0.05 1.6 ± 0.34 1.9 ± 0.30 3.8 ± 0.16 2.0 ± 0.41
Group VIII (Dx 10+Se-Met) 0.7 ± 0.29 1.3 ± 0.33 1.9 ± 0.40 1.1 ± 0.31 2.7 ± 0.61 2.4 ± 0.50
Group IX (Dx 10+D-Pt) 0.6 ± 0.11 1.3 ± 0.54 2.1 ± 0.70 1.3 ± 0.48 1.9 ± 0.13 1.5 ± 0.19
*P < 0.05 related to control, ***P < 0.001 related to control.
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with SeMet or D-Pt led to normalization of these indices to 
the level of the control animals (Table 3).
Study of activity of two crucial enzymes involved in glu-
tathione biosynthesis – glutathione reductase (GR) and 
glutathione transferase (GT) – revealed no differences in 
GR level, and a moderate increase (P < 0.05) of GT activity 
under Dx treatment (Table 4). SeMet and D-Pt in combi-
nation with Dx increased GR activity on the 14th day after 
tumor inoculation, but had no effect on GR level (Table 4). 
The most prominent changes in activity were observed for 
selenium-dependent glutathione peroxidase (GPx), the ac-
tivity of which dropped under Dx treatment (P < 0.05 com-
pared to health animals), and then was restored to the con-
trol level by SeMet administration. Measurement of overall 
GPx activity using another assay (30) showed a similar pat-
tern, except the decrease in total GPx activity in untreated 
tumor-bearing animals, which was not observed in the for-
mer assay (Table 4). There was no impact revealed at the 
action of D-Pt on activity of GPx, which suggests little im-
pact of vitamin B5 precursors on glutathione system. Se-
lenium’s role as a crucial component in coenzyme of GPx 
(15) might explain the observed impact of SeMet on in-
crease on activity of this enzyme, as it may recruit and acti-
vate extra number of holoenzymes, already present in cell 
cytosol.
Study of coenzyme A system revealed a significant drop in 
CoA fractions in the liver of tumor-bearing animals, which 
was not restored by Dx treatment or by combined therapy 
of Dx and SeMet (Table 5). Only D-Pt (physiological precur-
sor of CoA) restored concentrations of both acid-soluble 
and free CoA to the control levels, indicating its liver-pro-
tective potential, also confirmed by ALT/AST tests (Table 2).
diSCuSSiON
Our study revealed that D-Pt was the most effective dietary 
supplement, both enhancing the quality of life of NK/Ly 
lymphoma bearing animals and increasing Dx therapeutic 
tAbLe 4. Activity of glutathione reductase, glutathione transferase, selenium-dependent glutathione peroxidase and total GPx in the 






GPx(Н2О2), µM GSh/min/mg 
protein
GPx(t-bOOh), µM GSh/min/mg 
protein
Control (healthy) 21.3 ± 3.3 507.6 ± 48.8 340.52 ± 34.95 430.71 ± 49.86
Group I (C, NK/Ly) 21.2 ± 2.9 453.7 ± 16.9 389.92 ± 42.57 270.89 ± 74.50
Group II (Dx 5) 21.6 ± 0.2 584.3 ± 2.7* 261.57 ± 28.54 269.22 ± 29.75
Group III (Dx 5+Se-Met) 25.4 ± 1.4# 593.4 ± 30.3* 370.87 ± 18.41# 448.71 ± 83.10
Group IV (Dx 5+D-Pt) 28.8 ± 3.8 592.0 ± 65.4 284.61 ± 49.79 306.07 ± 8.43
 P < 0.05 related to control; * P < 0.05 related to control (NK/Ly); # P < 0.05 related to dx.
tAbLe 5. impact of selenomethionine, d-pantethine and doxorubicin (dx) on content of coenzyme A (CoA) fractions (nM/g of tissue) 
in the liver of NK/Ly lymphoma bearing animals
Groups Acid-soluble CoA Short-tailed CoA acyls Free CoA
Control (healthy) 293 ± 13 141 ± 8 152 ± 7
Group I (C, NK/Ly) 238 ± 14* 119 ± 11 119 ± 6*
Group II (Dx 5) 244 ± 11* 123 ± 7 121 ± 5*
Group III (Dx 5+Se-Met) 247 ± 12* 124 ± 9 122 ± 8*
Group IV (Dx 5+D-Pt) 282 ± 15 136 ± 8 146 ± 7#
* P < 0.05 related to control; # P < 0.05 related to dx.







nmol/mg protein GSh/GSSG eh. mV
Control (healthy) 3.94 ± 1.37 0.228 ± 0.091 4.40 ± 1.51 18.6 ± 5.8 -264.1 ± 5.4
Group I (C, NK/Ly) 8.77 ± 0.39* 0.309 ± 0.033 9.39 ± 0.34* 28.7 ± 2.2 -280.9 ± 0.6
Group II (Dx 5) 7.80 ± 0.26* 0.258 ± 0.027 8.32 ± 0.13* 30.6 ± 3.9 -280.2 ± 2.0
Group III (Dx 5+Se-Met) 5.92 ± 0.32# 0.263 ± 0.004 6.45 ± 0.32# 22.6 ± 1.0* -274.8 ± 1.3*#
Group IV (Dx 5+D-Pt) 5.34 ± 0.10# 0.232 ± 0.018 5.80 ± 0.11# 23.9 ± 2.3 -271.8 ± 0.8*#
*P < 0.05 related to control; P < 0.05 related to control (NK/Ly); #P < 0.05 related to dx.
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activity in vivo. In particular, combination therapy with D-Pt 
and Dx 5 mg/kg led to tumor remission (survival >60 days) 
in 100% animals, while in case of Dx 5 mg/kg alone animal 
survival time was 46-48 days. D-Pt decreased erythropenia 
and leukocytepenia induced by Dx, lowered neutrophilia 
and monocytosis, and restored the number of small lym-
phocytes in blood of tumor-bearing mice almost to the 
control level (in healthy animals) both on the 14th and 21st 
day after tumor inoculation. Thus, one can see that D-Pt 
may possess immunomodulating effect, which is in agree-
ment with other studies (37). Additionally, this antioxidant 
also had a moderate hepatoprotective effect, revealed in 
decrease of ALT/AST coefficient and recovery of CoA lev-
el in liver of NK/Ly lymphoma bearing animals under Dx 
treatment. However, NK/Ly lymphoma growth was accom-
panied by strong erythrocytosis and especially leukocyto-
sis (Figure 4), which significantly hinders interpretation of 
immunomodulatory activity of the studied antioxidants.
The use of D-Pt (500 mg/kg) together with higher doses 
of Dx (10 mg/kg) showed less notable results. This antioxi-
dant acted in the same way, decreasing leukocytopenia, 
erythropenia, monocytosis, and hepatotoxicity caused by 
Dox, and tumor-derived neutrophilia and leucopenia on 
the 14th day after tumor inoculation. However, no statis-
tically significant differences in these indices (except leu-
kocytopenia, erythropenia, and monocytosis) were ob-
served on the 21st day after tumor inoculation, meaning 
that high dose of Dx effectively treated animals with NK/
Ly lymphoma without any need for antioxidants. Surpris-
ingly, co-treatment of animals with Dx 10 mg/kg and D-Pt 
(500 mg/kg) led to remission only in 33% of tumor-bearing 
mice (survival >60 days), while in Dx 10 mg/kg group we 
observed 100% remission. This phenomenon cannot be 
explained by tumor regrowth or by cumulative toxicity of 
Dx, applied together with antioxidants, and thus needs to 
be clarified in more detail in further studies.
The same tendency, but to lower extent, was observed 
for SeMet. 600 µg/kg dose of this antioxidant partially re-
versed all side effects caused by low dose of Dx (5 mg/kg), 
but the overall survival rate in SeMet+Dx 5 mg/kg group 
was only 33% compared to 100% in D-Pt+Dx 5 mg/kg 
group, indicating lower tissue-protective capabilities of se-
lenium compared to vitamin B5 precursors. Combination 
of SeMet with higher doses of Dx (10 mg/kg) led to the 
same situation as in the case with D-Pt – remission only 
in 33% of tumor-bearing mice in contrast to 100% in Dx, 
and no differences in physiological indexes in comparison 
with Dx alone.
Studies of glutathione, coenzyme A levels, and activity of 
glutathione-converting enzymes indicate that SeMet and 
D-Pt realize their tissue-protecting activity in indirect way 
by influencing glutathione system in the cells. Moreover, 
flow cytometric studies have not revealed any ROS scav-
enging effect of SeMet and D-Pt under Dx treatment of 
Jurkat T-leukemia cells measured by DCFDA/DHE assays 
(data not presented). This principally distinguishes action 
of SeMet and D-Pt from other antioxidants already used in 
clinical medicine (eg, dexrazoxane), which act as iron ch-
elators and directly scavenge toxic superoxide anions pro-
duced by Dx (38). Nevertheless, SeMet and D-Pt also have 
significant benefits compared to dexrazoxane, as they may 
be administered orally as simple dietary supplements and 
possess strong immunomodulating properties, in contrast 
to dexrazoxane, which induces severe leukopenia in cancer 
patients (38). However, more studies should be performed 
to understand if the observed therapeutic efficiency of Se-
Met and D-Pt will be also preserved on other myeloid and 
solid tumor models. Additionally, tumor own negative im-
pact on health status of experimental animals, therapeutic 
effect of anticancer drugs toward tumor growth, their po-
tential side effects and finally the potential beneficial effect 
of antioxidants toward normal cells and tissues should be 
distinguished and analyzed in tight connection between 
each other.
In conclusion, selenomethionine and D-pantethine have 
demonstrated their ability to effectively protect the he-
matopoietic system and liver of tumor-bearing animals 
with NK/Ly lymphoma from the side effects of anticancer 
drug Dx, which was revealed by normalization of blood in-
dexes, animal weight, and ALT/AST activity. In overall, D-Pt 
demonstrated better tissue-protective and even therapeu-
tic activity compared to SeMet, leading to a significant in-
crease in survival of NK/Ly lymphoma bearing animals un-
der Dx treatment. However, tissue-protecting properties of 
the studied antioxidants may also depend on the dosage 
of anticancer drug. Both compounds enhance therapeutic 
action of low doses of Dx, but fail to increase survival of 
animals treated with high dose of Dx, though in both cases 
SeMet and D-Pt increase their quality of life. More studies 
on pharmacokinetics and potential interaction of antioxi-
dants with doxorubicin should be carried out before mak-
ing any conclusions on their potential application in clini-
cal practice. This will allow us to better understand if SeMet 
and D-Pt can enhance the therapeutic effect of Dx on my-
eloid tumors in cancer patients and thus increase their me-
dian survival time, which may be of high importance for 
development of novel schemes of cancer therapy based 
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on the combined use of anticancer drugs and antioxidant 
food supplements.
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